Clascoterone Side Effects: What Clinical Studies Show
Safety questions are the most common reason people hesitate before starting any anti-androgen. Clascoterone's dataset is unusual in that its largest trials were run in acne rather than alopecia, which still tells us a great deal about how the molecule behaves on skin.
Local, application-site reactions
The most frequently reported effects in trials were local and mild: erythema, scaling or dryness, pruritus and a stinging or burning sensation at the site of application. Most were graded mild and did not require discontinuation.
On the scalp, the alcohol-based vehicle common to topical solutions contributes to dryness independently of the active, which is why tolerability often improves after the first few weeks as the routine settles.
Systemic and hormonal findings
Because clascoterone is structurally related to cortexolone, trial programmes specifically monitored for hypothalamic-pituitary-adrenal axis suppression. In adult populations, clinically meaningful HPA axis suppression was not a general finding, though transient laboratory abnormalities were observed in a subset during intensive monitoring, particularly in adolescents with large treated surface areas.
Serum potassium changes were also monitored, as they are with systemic anti-androgens; no consistent clinically significant pattern emerged in the adult trial population.
Scalp application involves a considerably smaller surface area than full-face plus trunk acne treatment, which is relevant context when extrapolating systemic exposure.
Who should not use it without medical advice
- Anyone pregnant, planning pregnancy or nursing.
- People with an active scalp condition — psoriasis, seborrhoeic dermatitis flare, open lesions or sunburn.
- Anyone with an adrenal, pituitary or other endocrine diagnosis.
- People already using prescription topical or oral hormonal therapy.
- Anyone with a known hypersensitivity to the active or the vehicle.
Reducing the chance of irritation
- Begin with alternate-day application for the first one to two weeks.
- Apply to a dry scalp; damp skin increases penetration and stinging.
- Do not combine with a retinoid, exfoliating acid or microneedling on the same day.
- Stop and seek advice if you develop persistent redness, swelling or a rash.
References
- Hebert A, et al. Efficacy and Safety of Topical Clascoterone Cream 1% for Acne Vulgaris. — JAMA Dermatology, 2020
- Clascoterone (WINLEVI) prescribing information — adverse reactions and HPA axis data. — US FDA label
- Mazzetti A, et al. Pharmacokinetic profile and HPA axis assessment of clascoterone cream. — Clinical pharmacology literature
This library is educational. For the product itself — formulation, routine, pricing and shipping terms — return to the main website.
View the product